Arteriovenous Malformations

1.Obliteration over a latency period

The radiosurgical dose injures the nidus vessels, provoking intimal hyperplasia and progressive luminal closure that culminates in angiographically confirmed obliteration over roughly 2–4 years. Until obliteration is documented (catheter angiography remains the gold standard; MRI/MRA is a screen), the AVM continues to carry its natural hemorrhage risk, on the order of a few percent per year, so the latency window is a period of unprotected risk that must be discussed in consent. The untreated AVM bleeds at roughly 2–4% per year on average, higher in the first year after a rupture and with deep location, exclusively deep venous drainage, or an associated arterial/intranidal aneurysm.

Even after DSA-confirmed obliteration, surveillance should not simply stop. In a large multicenter cohort, post-obliteration hemorrhage and recurrent shunting were uncommon but measurable, approximately 0.72%/yr and 0.24%/yr, respectively. The practical message is reassuring but precise: cure transforms risk; it does not erase the need for long-term follow-up.

2.What predicts obliteration

Obliteration is driven chiefly by margin dose and nidus volume. Marginal doses commonly fall in the 16–25 Gy range (often ~18–21 Gy), with higher doses obliterating more reliably but constrained by eloquent-location tolerance. Smaller AVMs obliterate far better: small niduses reach obliteration rates around 70–90%+, whereas large AVMs do substantially worse with single-session treatment. Prognostic scores formalize this: the surgical Spetzler-Martin grade guides resection, while radiosurgery-specific scores predict obliteration without new deficit and are the right tools for radiosurgical selection: the Pollock-Flickinger radiosurgery-based score (nidus volume, patient age, and location) and the Virginia Radiosurgery AVM Scale (VRAS) (nidus volume, eloquent location, and prior hemorrhage). The Pollock-Flickinger score, for example, sums weighted terms for nidus volume, patient age, and location (roughly 0.1 × volume in cc + 0.02 × age in years + 0.3 × location), with lower scores predicting obliteration without new deficit.

3.Volume-staged approaches and repeat SRS

Large AVMs exceed the volume at which a single tumoricidal-margin session is safe. Volume-staged SRS, treating anatomic subvolumes of the nidus in separate sessions months apart, is the established strategy and is what most high-volume centers use above roughly 10–15 cc. Dose-staged and hypofractionated regimens are less established, and some large-series centers hold that fractionation schemes have no current role in AVM. For residual nidus after the latency period, repeat SRS at 3–5 years is a standard salvage option, with pooled obliteration around 59% after the second treatment. Embolization has a clear role in obliterating associated aneurysms before SRS, but as a volume-reducing maneuver it is discouraged: matched series show obliteration falling from roughly 70% without prior embolization to roughly 47% with it, because recanalization and a fragmented, poorly defined target degrade the plan.

4.Latency hemorrhage and radiation effects

The principal risks are hemorrhage during the latency period (the AVM is not yet protected), adverse radiation effects (perinidal edema/T2 change is common on imaging, symptomatic in a minority) and, less commonly, late cyst formation and radionecrosis. Risk rises with larger treated volume and higher dose to eloquent tissue, the same variables that govern obliteration, so dose selection is an explicit balance between obliteration probability and radiation injury.

5.To treat an unruptured AVM, or not

ARUBA randomized patients with unruptured brain AVMs to medical management versus intervention and found fewer deaths or symptomatic strokes with medical management over both the initial short follow-up and the later final analysis. The trial reshaped the conversation but remains debated: the intervention arm was heterogeneous (surgery, embolization, SRS, and combinations), did not isolate radiosurgery, and the follow-up remains short relative to a young patient's lifetime hemorrhage horizon and the latency of SRS. ARUBA therefore does not answer whether a carefully selected small, surgically difficult AVM benefits from radiosurgery. Crucially, ruptured AVMs were excluded. Prior rupture strengthens the rationale for definitive obliteration, but the choice among microsurgery, embolization, SRS, combinations, or observation still depends on angioarchitecture, location, treatment risk, and patient goals.

6.ARUBA and the unruptured-AVM debate

Unlike brain metastases, AVM radiosurgery rests on one dominant randomized trial, and it remains the most argued result in the field. Guideline-level evidence otherwise comes from pooled series graded by Spetzler-Martin grade. TOBAS, an ongoing pragmatic randomized trial, has not reported.

Open controversies:

• The ARUBA critique. The trial's short follow-up is mismatched to a lifelong hemorrhage risk and to the multi-year SRS latency; it pooled heterogeneous interventions (surgery, embolization, radiosurgery, and combinations) and enrolled few radiosurgery-only patients. Many centers still offer SRS to selected unruptured AVMs (small, surgically difficult, or high-future-risk lesions in younger patients) while accepting ARUBA as a caution against reflexive intervention.
• The latency-period risk. SRS does not protect against hemorrhage until obliteration occurs, 2–4 years later; whether that interval is acceptable depends on the lesion's bleeding risk and the patient's age.
• Large AVMs. Single-session SRS underperforms above ~10 cc; volume-staged and dose-staged approaches, and combinations with embolization, are options of unsettled comparative merit.
• Ruptured versus unruptured. ARUBA does not apply to ruptured AVMs, where the case for obliteration is far stronger: the distinction that must anchor every AVM discussion.